Role of interleukin-2 regulated proteins in immunosuppression by the N-alkylated prodigiosin analogue

International Immunopharmacology

Volumn 7, Issue 13, 2007, Pages 1695-1703

  Pandey, Ruchi ^a   Chander, Ramesh ^a   Sainis, Krishna B ^b  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

^b Modular Laboratories   (India)

Author keywords

Apoptosis; Cell cycle arrest; Immunosuppression; Interleukin 2; Prodigiosin; Signaling

Indexed keywords

2,2 [3 METHOXY 1' AMYL 5' METHYL 4 (1'' PYRRYL)]DIPYRRYL METHENE; CD71 ANTIGEN; CYCLIN D; CYCLINE; FAS ANTIGEN; INTERLEUKIN 2; PRODIGIOSIN; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; IMMUNOSUPPRESSIVE TREATMENT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SPLEEN CELL;

ALKENES; ANIMALS; ANTIGENS, CD; ANTIGENS, CD95; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; APOPTOSIS; CELL DIVISION; CYCLINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; MALE; MICE; PRODIGIOSIN; PROLIFERATING CELL NUCLEAR ANTIGEN; PYRROLES; RECEPTORS, TRANSFERRIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 35748965856     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2007.08.024     Document Type: Article

References (42)

1. Sun E.W., and Shi Y.F. Apoptosis: the quiet death silences the immune system. Pharmacol Therapeut 91 (2001) 135-145
2. Shi Y.F., Sahai B.M., and Green D.R. Cyclosporin A inhibits activation-induced cell death in T-cell hybridomas and thymocytes. Nature 339 (1989) 625-626
3. Li Y., Li X.C., Zheng X.X., Wells A.D., Turka L.A., and Strom T.B. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 5 (1999) 1298-1302
4. Nakamura A., Nagai K., Ando K., and Tamura G. Selective suppression by prodigiosin of the mitogenic response of murine splenocytes. J Antibiot (Tokyo) 39 (1986) 1155-1159
5. Kawauchi K., Shibutani K., Yagisawa H., Kamata H., Nakatsuji S., Anzai H., et al. A possible immunosuppressant, cycloprodigiosin hydrochloride, obtained from Pseudoalteromonas denitrificans. Biochem Biophys Res Commun 237 (1997) 543-547
6. Songia S., Mortellaro A., Taverna S., Fornasiero C., Scheiber E.A., Erba E., et al. Characterization of the new immunosuppressive drug undecylprodigiosin in human lymphocytes: retinoblastoma protein, cyclin-dependent kinase-2, and cyclin-dependent kinase-4 as molecular targets. J Immunol 158 (1997) 3987-3995
7. Mortellaro A., Songia S., Gnocchi P., Ferrari M., Fornasiero C., D'Alessio R., et al. New immunosuppressive drug PNU156804 blocks IL-2-dependent proliferation and NF-kappa B and AP-1 activation. J Immunol 162 (1999) 7102-7109
8. Azuma T., Watanabe N., Yagisawa H., Hirata H., Iwamura M., and Kobayashi Y. Induction of apoptosis of activated murine splenic T cells by cycloprodigiosin hydrochloride, a novel immunosuppressant. Immunopharmacology 46 (2000) 29-37
9. Lee M.H., Kataoka T., Honjo N., Magae J., and Nagai K. In vivo rapid reduction of alloantigen-activated CD8+ mature cytotoxic T cells by inhibitors of acidification of intracellular organelles, prodigiosin 25-C and concanamycin B. Immunology 99 (2000) 243-248
10. Han S.B., Park S.H., Jeon Y.J., Kim Y.K., Kim H.M., and Yang K.H. Prodigiosin blocks T cell activation by inhibiting interleukin-2Ralpha expression and delays progression of autoimmune diabetes and collagen-induced arthritis. J Pharmacol Exp Ther 299 (2001) 415-425
11. Han S.B., Lee C.W., Yoon Y.D., Kang J.S., Lee K.H., Yoon W.K., et al. Effective prevention of lethal acute graft-versus-host disease by combined immunosuppressive therapy with prodigiosin and cyclosporine A. Biochem Pharmacol 70 (2005) 1518-1526
12. Stepkowski S.M., Erwin-Cohen R.A., Behbod F., Wang M.E., Qu X., Tejpal N., et al. Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood 99 (2002) 680-689
13. Variyar P.S., Chander R., Venkatachalam S.R., and Bongirwar D.R. A new red pigment from an alkalophilic Micrococcus species. Indian J Chem 41 (2002) 232-233
14. Deorukhkar A.A., Chander R., Ghosh S.B., and Sainis K.B. Identification of a red-pigmented bacterium producing a potent anti-tumor N-alkylated prodigiosin as Serratia marcescens. Res Microbiol 158 (2007) 399-404
15. Pandey R., Chander R., and Sainis K.B. A novel prodigiosin-like immunosuppressant from an alkalophilic Micrococcus sp. Int Immunopharmacol 3 (2003) 159-167
16. Meikrantz W., and Schlegel R. Apoptosis and the cell cycle. J Cell Biochem 58 (1995) 160-174
17. Lyons A.B., and Parish C.R. Determination of lymphocyte division by flow cytometry. J Immunol Methods 171 (1994) 131-137
18. Neckers L.M., and Cossman J. Transferrin receptor induction in mitogen-stimulated human T lymphocytes is required for DNA synthesis and cell division and is regulated by interleukin 2. Proc Natl Acad Sci USA 80 (1983) 3494-3498
19. Kronke M., Leonard W.J., Depper J.M., and Greene W.C. Sequential expression of genes involved in human T lymphocyte growth and differentiation. J Exp Med 161 (1985) 1593-1598
20. Gaffen S.L. Signaling domains of the interleukin 2 receptor. Cytokine 14 (2001) 63-77
21. Moore K.S., Sullivan K., Tan E.M., and Prystowsky M.B. Proliferating cell nuclear antigen/cyclin is an interleukin 2-responsive gene. J Biol Chem 262 (1987) 8447-8450
22. Kurki P., Lotz M., Ogata K., and Tan E.M. Proliferating cell nuclear antigen (PCNA)/cyclin in activated human T lymphocytes. J Immunol 138 (1987) 4114-4120
23. Seiser C., Teixeira S., and Kuhn L.C. Interleukin-2-dependent transcriptional and post-transcriptional regulation of transferrin receptor mRNA. J Biol Chem 268 (1993) 13074-13080
24. Ouyang Q., Bommakanti M., and Miskimins W.K. A mitogen-responsive promoter region that is synergistically activated through multiple signalling pathways. Mol Cell Biol 13 (1993) 1796-1804
25. Hirsch S., and Miskinins W.K. Mitogen induction of nuclear factors that interact with a delayed responsive region of the transferrin receptor gene promoter. Cell Growth Differ 6 (1995) 719-726
26. Huang D., Shipman-Appasamy P.M., Orten D.J., Hinrichs S.H., and Prystowsky M.B. Promoter activity of the proliferating-cell nuclear antigen gene is associated with inducible CRE-binding proteins in interleukin 2-stimulated T lymphocytes. Mol Cell Biol 14 (1994) 4233-4243
27. Perez-Tomas R., and Montaner B. Effects of the proapoptotic drug prodigiosin on cell cycle-related proteins in Jurkat T cells. Histol Histopathol 18 (2003) 379-385
28. Harbour J.W., and Dean D.C. The pRb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 14 (2000) 2393-2409
29. Adams P.D. Regulation of the retinoblastoma tumor suppressor protein by cyclin/CDKs. Biochim Biophys Acta 1471 (2001) 123-133
30. Herber B., Truss M., Beato M., and Muller R. Inducible regulatory elements in the human cyclin D1 promoter. Oncogene 9 (1994) 1295-1304
31. Guttridge D.C., Albanese C., Reuther J.Y., Pestell R.G., and Baldwin Jr. A.S. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19 (1999) 5785-5799
32. Hinz M., Krappmann D., Eichten A., Heder A., Scheidereit C., and Strauss M. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 19 (1999) 2690-2698
33. Albanese C., D'Amico M., Reutens A.T., Fu M., Watanabe G., Lee R.J., et al. Activation of the cyclin D1 gene by the E1A-associated protein p300 through AP-1 inhibits cellular apoptosis. J Biol Chem 274 (1999) 34186-34195
34. Kamata K., Okamoto S., Oka S., Kamata H., Yagisawa H., and Hirata H. Cycloprodigiosin hydrocloride suppresses tumor necrosis factor (TNF)-α induced transcriptional activation by NF-κB. FEBS Lett 507 (2000) 74-80
35. Montaner B., and Perez-Tomas R. The cytotoxic prodigiosin induces phosphorylation of p38-MAPK but not of SAPK/JNK. Toxicol Lett 129 (2002) 93-98
36. Van Parijs L., and Abbas A.K. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280 (1998) 243-248
37. Colman M.S., Afshari C.A., and Barrett J.C. Regulation of p53 stability and activity in response to genotoxic stress. Mutat Res 462 (2000) 179-188
38. Milner J., and Milner S. SV40-53K antigen: a possible role for 53K in normal cells. Virology 112 (1981) 785-788
39. Reed J.C., Alpers J.D., Nowell P.C., and Hoover R.G. Sequential expression of protooncogenes during lectin-stimulated mitogenesis of normal human lymphocytes. Proc Natl Acad Sci USA 83 (1986) 3982-3986
40. Reich N.C., and Levine A.J. Growth regulation of a cellular tumour antigen, p53, in nontransformed cells. Nature 308 (1984) 199-201
41. Castillo-Avila W., Abal M., Robine S., and Perez-Tomas R. Non-apoptotic concentrations of prodigiosin (H+/Cl- symporter) inhibit the acidification of lysosomes and induce cell cycle blockage in colon cancer cells. Life Sci 78 (2005) 121-127
42. Wu H., and Lozano G. NF-kappa B activation of p53. A potential mechanism for suppressing cell growth in response to stress. J Biol Chem 269 (1994) 20067-20074